Market Entry into Europe for MedTech
Navigate MDR and IVDR requirements with a de-risked, first-time-right approach.
Success under MDR and IVDR depends on clinical evidence strategy, QMS alignment, and early Notified Body preparation. QbD Group combines regulatory, quality, and clinical expertise into a first-time-right approach for Medical Device and IVD manufacturers entering Europe.
Start with a strategic EU market entry workshop
Not sure where to begin? Our structured workshop gives you a clear picture of your regulatory starting point, key risks, and a prioritized 90-day action plan. It is the fastest way to align your team and move forward without wasting time.
Where is your company based?
Your European market entry strategy depends on your starting point. Regulatory expectations, clinical evidence requirements, and typical EU entry risks vary significantly between US and Chinese MedTech manufacturers. Select your market to see how we tailor your EU entry strategy.
From FDA to MDR/IVDR
Understand key EU regulatory differences, translate your clinical evidence to meet EU expectations, and plan a Notified Body pathway tailored to your product. We help identify gaps, streamline documentation, and reduce time to market.
Learn more
From NMPA to MDR/IVDR
Navigate EU regulatory and clinical requirements, adapt your existing evidence, and address Notified Body expectations. We guide you through gaps in compliance, optimize documentation, and accelerate your European entry.
Learn more
From Global Markets to MDR/IVDR
Whether you're based in Japan, South Korea, Australia, or another non-EU market, we tailor your EU entry strategy to your regulatory background and clinical evidence. Contact us to discuss your specific situation.
Learn moreKey challenges we address
Notified Body backlogs
NB capacity is limited and timelines are unpredictable. Early preparation is the only way to avoid delays.
FDA clinical data not accepted as-is
EU requires a different clinical evidence structure. Gaps need to be identified and addressed early.
No EU Authorized Representative in place
Non-EU manufacturers need a legal EU presence before placing products on the market.
Unclear market access and distribution path
Knowing how to get CE-marked does not tell you how to reach patients. Distribution strategy and reimbursement planning are often overlooked.
How we work with you.
EU Readiness Assessment
Evaluate your current regulatory, clinical, and quality status against MDR/IVDR requirements.
Gap Analysis
Identify what is missing and prioritize actions by risk and timeline impact.
Regulatory Pathway Design
Define your Notified Body route, clinical evidence strategy, and QMS alignment plan.
Submission and Certification Support
Manage documentation, NB interactions, and audit preparation through to CE mark.
Post-Market and Distribution Setup
Put post-market surveillance, vigilance, and market access groundwork in place.
Our structured approach
From FDA or NMPA to MDR/IVDR
Understand key EU regulatory differences, translate your clinical evidence, adapt existing data to meet EU expectations, and plan a Notified Body pathway tailored to your product.
Gap analysis & documentation
Identify gaps, streamline documentation, and reduce time to market with expert regulatory guidance.
Sustainable compliance
Achieve sustainable compliance with lifecycle management and post-market surveillance support.
Why EU Market Entry Requires Expert Guidance
MDR and IVDR compliance demands strategic planning across regulatory, clinical, and quality domains from day one.
What you gain
Multi-country access
A single CE mark enables access to multiple EU countries and healthcare systems.
Reduced uncertainty
Move faster and reduce uncertainty with expert regulatory and clinical guidance from day one.
First-time-right approach
Avoid rework and delays by getting it right the first time with integrated support.
Why QbD Group
Your trusted EU market entry partner for Medical Devices and IVDs.
Deep MDR & IVDR expertise — 700+ specialists with hands-on experience across all device classes and risk categories
First-time-right approach — structured gap analysis
documentation, and Notified Body preparation to avoid rework and delays
End-to-end EU market entry — integrated regulatory
clinical, quality, and post-market services under one roof
Proven track record with non-EU manufacturers — tailored strategies for FDA-cleared and NMPA-approved companies entering Europe
European regulatory network — direct experience with leading Notified Bodies and in-depth knowledge of member-state requirements
Scalable partnership model — from strategic advisory to full operational support
adapting to your project needs and timelines
How we guide your EU market entry
Tailored support across regulatory, clinical, quality, and post-market domains for medical device and IVD manufacturers.
Regulatory Pathway
Navigate MDR and IVDR with expert guidance.
- Product classification and regulatory strategy
- Technical documentation and Notified Body preparation
- Gap analysis and remediation planning
Clinical Evidence
Build the right clinical evidence strategy for EU requirements.
- Clinical evaluation report preparation
- PMCF study design and execution
- Literature review and equivalence assessment
QMS Alignment
Align your quality systems with EU expectations.
- ISO 13485 gap assessment and implementation
- Design control and risk management alignment
- Supplier qualification for EU requirements
Post-Market Compliance
Maintain compliance throughout the product lifecycle.
- Post-market surveillance planning
- Vigilance reporting and PSUR preparation
- Periodic safety update management
Client cases
Recent client cases
See how we helped MedTech companies navigate EU market entry and clinical requirements.
ClinicalMulti-Country Clinical Trial for CE-Mark Success in the UK
Navigating complex UK regulations to deliver a seamless, multi-country clinical trial for coronary artery disease
- Challenge: Client needed critical data for their CE-mark application through a multi-country clinical trial, facing the complexities of navigating UK regulatory requirements, which many companies avoid due to its challenges.
- Approach: Full support for the LiquID Safety study from start-up to closure. Study monitoring, regulatory submissions, and project oversight. Streamlined UK submission processes and leveraged top-tier UK investigational sites for the study.
- Result: The study enrolled 86 subjects across Belgium, UK, and Scotland, and was completed successfully in Q1 2024. Demonstrated the value of UK investigational sites in a First-in-Human trial for coronary artery disease. The positive outcome led to further collaborations, with the client recommending our services to other clients.
ClinicalEmpowering a First-In-Human Clinical Trial Success
Expert guidance and seamless project management for breakthrough medical innovations in heart failure treatment
- Challenge: Client faced difficulties navigating the complex EU regulatory landscape to set up and manage their first multi-country clinical trial for the V-LAP System, without prior EU trial management experience.
- Approach: Initially covered the UK, expanding to Spain and offering consultancy and project management support. Assigned experienced CRAs for trial monitoring, regulatory submissions, and document creation. Provided comprehensive advisory services to ensure compliance with EU standards.
- Result: 30 subjects enrolled across five countries for the ongoing First-in-Human study. Successful start-up phase completion and knowledge transfer enabled Vectorious to manage many trial aspects independently. Strong collaboration led to future project opportunities through industry referrals.
FAQ
Frequently asked questions
Ready to enter the European MedTech market?
Tell us about your product and goals. We'll help you navigate EU regulations and move toward European patients with confidence.